Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation

Kroger, N; Zander, AR; Martinelli, G; Ferrante, P; Moraleda, JM; Da Prada, GA; Demirer, TANER; Socie, G; Rosti, G

doi:10.1093/annonc/mdg161

Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation

Kroger N., Zander A., Martinelli G., Ferrante P., Moraleda J., Da Prada G., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.14, sa.4, ss.554-558, 2003 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 14 Sayı: 4
Basım Tarihi: 2003
Doi Numarası: 10.1093/annonc/mdg161
Dergi Adı: ANNALS OF ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.554-558
Anahtar Kelimeler: acute myeloid leukemia, adjuvant therapy, breast cancer, high-dose chemotherapy, secondary myelodysplasia, ACUTE MYELOGENOUS LEUKEMIA, STEM-CELL TRANSPLANTATION, CYCLOPHOSPHAMIDE, RISK, MITOXANTRONE, MALIGNANCIES, EXPERIENCE, RADIATION, ABNORMALITIES, FLUOROURACIL
Ankara Üniversitesi Adresli: Evet

Özet

Background: To determine the incidence of secondary myelodysplasia (sMDS) or acute myeloid leukemia (AML) in node-positive breast cancer patients who received high-dose chemotherapy (HDCT) followed by autologous stem-cell support as adjuvant therapy.